Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
63.193,61
0,48%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Mind Medicine MindMed Inc (MNMD) Mind Medicine MindMed Inc (MNMD) Notizie

MNMD

Mind Medicine MindMed (MNMD)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:MNMD
DataOraFonteTitoloSimboloCompagnia
02/05/202413:00Business WireMindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business UpdateNASDAQ:MNMDMind Medicine MindMed Inc
25/04/202413:00Business WireMindMed to Present at Upcoming May Medical ConferencesNASDAQ:MNMDMind Medicine MindMed Inc
02/04/202413:00Business WireMindMed to Present at Upcoming April Medical ConferencesNASDAQ:MNMDMind Medicine MindMed Inc
01/04/202423:00Business WireMindMed Announces Voluntary Delisting from Cboe CanadaNASDAQ:MNMDMind Medicine MindMed Inc
11/03/202413:32Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNMDMind Medicine MindMed Inc
11/03/202412:00Business WireMindMed to Participate in the Leerink Partners 2024 Global Biopharma ConferenceNASDAQ:MNMDMind Medicine MindMed Inc
07/03/202413:13Business WireMind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private PlacementNASDAQ:MNMDMind Medicine MindMed Inc
07/03/202413:09Edgar (US Regulatory)Form S-3MEF - Registration adding securities to prior Form S-3 registration [Rule 462(b)]NASDAQ:MNMDMind Medicine MindMed Inc
07/03/202412:00Business WireMindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety DisorderNASDAQ:MNMDMind Medicine MindMed Inc
01/03/202419:56Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MNMDMind Medicine MindMed Inc
01/03/202415:00Business WireMindMed to Host Conference Call and Webcast to Discuss Data Update for MM120NASDAQ:MNMDMind Medicine MindMed Inc
29/02/202422:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNMDMind Medicine MindMed Inc
28/02/202413:20Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:MNMDMind Medicine MindMed Inc
28/02/202413:05Business WireMindMed Reports 2023 Financial Results and Business UpdatesNASDAQ:MNMDMind Medicine MindMed Inc
22/02/202413:00Business WireMindMed to Host Conference Call and Webcast to Discuss 2023 Financial Results and Provide Business UpdateNASDAQ:MNMDMind Medicine MindMed Inc
07/02/202413:00Business WireMindMed to Participate in the 34th Annual Oppenheimer Healthcare Life Sciences ConferenceNASDAQ:MNMDMind Medicine MindMed Inc
08/01/202413:45Business WireMindMed Announces Business Update and Anticipated Milestones for 2024NASDAQ:MNMDMind Medicine MindMed Inc
14/12/202313:30Business WireMindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety DisorderNASDAQ:MNMDMind Medicine MindMed Inc
02/11/202321:20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MNMDMind Medicine MindMed Inc
02/11/202321:01Business WireMindMed Reports Third Quarter 2023 Financial Results and Business HighlightsNASDAQ:MNMDMind Medicine MindMed Inc
26/10/202313:30Business WireMindMed to Host Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Business UpdateNASDAQ:MNMDMind Medicine MindMed Inc
24/10/202313:30Business WireMindMed Completes Enrollment of Phase 2a Trial of MM-120 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)NASDAQ:MNMDMind Medicine MindMed Inc
03/10/202313:30Business WireMindMed to Present Data on the Preclinical Activity of MM-402 at the 36th Annual European College of Neuropsychopharmacology (ECNP) CongressNASDAQ:MNMDMind Medicine MindMed Inc
15/09/202323:27Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:MNMDMind Medicine MindMed Inc
14/09/202313:30Business WireMindMed to Participate in the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry SummitNASDAQ:MNMDMind Medicine MindMed Inc
12/09/202313:30Business WireMindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)NASDAQ:MNMDMind Medicine MindMed Inc
28/08/202313:30Business WireMindMed to Participate at September Investor ConferencesNASDAQ:MNMDMind Medicine MindMed Inc
14/08/202313:30Business WireMindMed Secures $50.0 Million Credit Facility with K2 HealthVenturesNASDAQ:MNMDMind Medicine MindMed Inc
03/08/202322:01Business WireMindMed Reports Second Quarter 2023 Financial Results and Business HighlightsNASDAQ:MNMDMind Medicine MindMed Inc
03/08/202313:30Business WireMindMed Announces Exclusive License Agreement With Catalent for Its Patented Zydis® Fast-Dissolve Technology for Use with MM-120NASDAQ:MNMDMind Medicine MindMed Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:MNMD

La tua Cronologia

BIT
ISP
Intesa Sanpaolo
BIT
UCG
Unicredit
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
STLAM
Stellantis NV
BIT
ENEL
Enel
BIT
STMMI
ST Microelectronics
BIT
BPE
Bper Banca
BIT
BAMI
Banco BPM
BIT
ENI
Eni
BIT
RACE
Ferrari NV
BIT
TIT
Telecom Italia
BIT
SPM
Saipem
BIT
SRG
Snam
BIT
TEN
Tenaris
BIT
TRN
Terna Trasmissione Elett...
BIT
IVG
Iveco Group NV
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network